Exhibit 99.1
22 August 2024
PureTech Health
plc
PureTech Appoints Michele Holcomb, PhD, to Board of Directors
Strategic healthcare leader brings more than 30 years of global experience to PureTech’s Board following notable positions with
Cardinal Health, Teva Pharmaceuticals and McKinsey & Company
PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) (“PureTech” or
the “Company”), a clinical-stage biotherapeutics company dedicated to changing the lives of patients with devastating diseases, today announced that Michele Holcomb, PhD, will join its board of directors as an independent non-executive director. Dr. Holcomb’s appointment will take effect as of September 23, 2024. She brings more than 30 years of expertise leading global healthcare companies through strategic inflection points
and preparing innovative programs and portfolios for growth.
“As PureTech enters its next phase of growth focused on innovating and progressing
major advances for patients, Dr. Holcomb brings a wealth of experience to our strategy that’s built among highly visible healthcare organizations,” said Bharatt Chowrira, PhD, JD, Chief Executive Officer of PureTech. “She has a
proven track record of leading transformational growth initiatives and driving organizational progress that will complement our board’s exceptional leadership, and we will greatly benefit from Dr. Holcomb’s broad biopharma experience
as we deliver on our commitment to bring highly innovative and differentiated new medicines to patients and build value for all of our shareholders.”
“PureTech pioneered the hub-and-spoke business model, and its approach
successfully combines commercial, scientific and medical expertise towards a highly focused development strategy for each of the therapies in its portfolio,” commented Dr. Holcomb. “I am excited and honored to work with my fellow
board members and the PureTech management team to guide the Company through the next stage of evolution.”
Dr. Holcomb is a strategic leader
with more than 30 years of healthcare experience across biotech, pharmaceuticals and healthcare services. She has served on both public and private boards, and has been a scientist, consultant and executive, driving change through innovation and
optimization at key interfaces. In her previous role as EVP, Chief Strategy and Business Development Officer at Cardinal Health, Dr. Holcomb leveraged an enterprise perspective and knowledge of the evolving healthcare landscape to work with the
CEO, CFO, and leaders across the Pharmaceutical and Medical segments to define strategies, optimize the portfolio, and identify growth and innovation opportunities. Her team also led the execution and integration of investments, acquisitions,
partnerships and divestitures to support Cardinal Health’s strategy, as well as drove the enterprise approach to innovation.
Prior to Cardinal
Health, Dr. Holcomb was the Chief Operating Officer of Global R&D and SVP of Strategy, Portfolio, Search and Partnerships at Teva Pharmaceuticals. She also spent 15 years at McKinsey & Company and was a Partner of the Global
Pharmaceutical Practice. Dr. Holcomb is a member of the board of directors and chair of the Nominating and ESG (NESG) committee of Kimball Electronics Inc (Nasdaq: KE). She also serves on the board of the Abigail Wexner Research Institute at
Nationwide Children’s Hospital in Columbus, the BalletMet of Columbus, where she chairs the long-range planning committee and the Liberty Science Center in New Jersey. Dr. Holcomb is a member of the editorial advisory board of
Pharmaceutical Executive and has lectured on healthcare strategy at Kellogg (Northwestern), Columbia and Fuqua (Duke) business schools. Dr. Holcomb received a BS in chemistry from Stanford University and a PhD in chemistry from the
University of California, Berkeley, and previously worked as an R&D chemist at Ciba-Geigy and Syntex Pharmaceuticals.